Comparative Pharmacology
Head-to-head clinical analysis: CRYSTODIGIN versus LANOXIN PEDIATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRYSTODIGIN versus LANOXIN PEDIATRIC.
CRYSTODIGIN vs LANOXIN PEDIATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium, which in turn promotes calcium influx via the Na+/Ca2+ exchanger, resulting in increased myocardial contractility (positive inotropy). It also has negative chronotropic and dromotropic effects via vagomimetic action.
Inhibition of Na+/K+ ATPase leading to increased intracellular calcium and positive inotropy.
0.5 mg intravenously over 2-4 hours, then 0.25 mg every 6 hours as needed up to a total of 1.5 mg in 24 hours.
Adult: Oral loading dose 0.75-1.5 mg in divided doses over 24-48 hours. Maintenance: 0.125-0.5 mg once daily. Intravenous: Loading dose 0.5-1 mg over 10-20 minutes, then maintenance 0.125-0.5 mg once daily.
None Documented
None Documented
Terminal elimination half-life approximately 1.6–1.9 days (38–45 hours) in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is 36-48 hours in adults with normal renal function; prolonged to 3.5-5 days in anephric patients due to reduced renal clearance.
Primarily renal excretion of unchanged drug; ~80-90% eliminated in urine, ~10-20% in feces via biliary excretion.
Renal excretion of unchanged drug accounts for 60-80% of elimination; nonrenal clearance is 20-40% (biliary/fecal).
Category C
Category C
Cardiac Glycoside
Cardiac Glycoside